(2S)-3-[(But-3-en-1-yl)sulfanyl]-2-methylpropanoic acid | 824429-31-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-3-[(But-3-en-1-yl)sulfanyl]-2-methylpropanoic acid
• 英文别名: (2S)-3-but-3-enylsulfanyl-2-methylpropanoic acid
• CAS: 824429-31-4
• 化学式: C₈H₁₄O₂S
• 分子量: 174.26
• InChiKey: XHFOVIDLSWUWAU-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (S)-(-)-3-硫代乙酰-2-甲基丙酸 、 4-溴-1-丁烯 、 sodium hydroxide 、 水 、 盐酸 在 乙酸乙酯 、 水 、 Brine 、 magnesium sulfate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 (2S)-3-[(But-3-en-1-yl)sulfanyl]-2-methylpropanoic acid
  参考文献：
  名称：

  MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF

  摘要：

  本发明涉及公式（I）的大环化合物，其中R1是（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷基硫基（C1-4）烷基，（C1-6）烯基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，哌啶基或吡咯烷基，R2和R4分别是氢或可选择取代的（C1-8）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，芳基，芳基（C1-4）烷基，杂环芳基或杂环芳基（C1-4）烷基，或R2和R4与它们连接的氮一起形成可选择取代的哌啶基，吡咯烷基，吗啉基或哌嗪基，R3是氢或（C1-4）烷基，X1是CH2，X2是CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，其中R是氢或（C1-4）烷基，Y是（C1-8）烷基或（C1-8）烷氧基（C1-6）烷基，（C1-8）烯基或（C1-8）烯氧基（C1-6）烷基，Ar是苯环，可选择单取代，二取代或三取代，独立的取代基为羟基或卤素，其中X1和X2相对于彼此处于间位或对位，且Z要么是CO，AA是天然或非天然α-氨基酸，n为0或1，要么Z是S02，AA是可选择取代的乙烯基羰基基团（通过将氮替换为甲基烷基团从天然或非天然α-氨基酸衍生而来），n为1；制备这些化合物的方法；包括这些化合物的药物组合物和制剂；以及它们在治疗与β-淀粉样蛋白生成和/或聚集有关的神经和血管疾病中的用途。

  公开号：

  US20080070885A1

文献信息

• [EN] MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF<br/>[FR] COMPOSES MACROCYLIQUES PRESENTANT UNE ACTIVITE D'INHIBITION DE PROTEASE ASPARTIQUE ET UTILISATIONS PHARMACEUTIQUES DE CEUX-CI
  申请人：NOVARTIS AG

  公开号：WO2005003106A1

  公开（公告）日：2005-01-13

  The present invention relates to macrocyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-­7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, piperidinyl or pyrrolidinyl, R2 and R4, independently, are hydrogen or optionally substituted (C1-8)alkyl, (C3-7) cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl, aryl(C1-4)alkyl, heteroaryl or heteroaryl(C1-4) alkyl, or R2 and R4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R3 is hydrogen or (C1-4)alkyl, X1 is CH2, X2 is CH2, O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C1-4)alkyl, Y is (C1-8)alkylen or (C1-­8)alkylenoxy(C1-6)alkylen, (C1-8)alkenylen or (C1-8)alkenylenoxy(C1-6)alkylen, Ar is a phenyl ring optionally mono- di­ or trisubstituted by, independently, hydroxy or halogen, whereby X1, and X2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S02, AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及式(I)的大环化合物，其中R1为(C1-8)烷基，(C1-4)烷氧基(C1-4)烷基，羟基(C1-6)烷基，(C1-4)烷基硫基(C1-4)烷基，(C1-6)烯基，(C3-7)环烷基，(C3-7)环烷基(C1-4)烷基，哌啶基或吡咯啉基，R2和R4，独立地，为氢或可选择取代的(C1-8)烷基，(C3-7)环烷基，(C3-7)环烷基(C1-4)烷基，芳基，芳基(C1-4)烷基，杂环芳基或杂环芳基(C1-4)烷基，或R2和R4与它们连接的氮一起形成可选择取代的哌啶基，吡咯啉基，吗啉基或哌嗪基，R3为氢或(C1-4)烷基，X1为CH2，X2为CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，R为氢或(C1-4)烷基，Y为(C1-8)烷基或(C1-8)烷氧基(C1-6)烷基，(C1-8)烯基或(C1-8)烯氧基(C1-6)烷基，Ar为苯环，可选择单取代、双取代或三取代，取代基为羟基或卤素，其中X1和X2在彼此的间位或对位，且Z为CO时，AA为天然或非天然的α-氨基酸，n为0或1；或Z为SO2时，AA为可选择取代的乙烯羰基团（由天然或非天然的α-氨基酸通过用甲基烷基替换氮而得到），n为1；制备这些化合物的方法；包含这些化合物的药物组合物和药物组合物；以及它们在治疗与β-淀粉样蛋白生成和/或聚集相关的神经和血管疾病中的用途。
• Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
  申请人：Betschart Claudia

  公开号：US20060223745A1

  公开（公告）日：2006-10-05

  The present invention relates to macrocyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 )alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-6 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is SO 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及式（I）的大环化合物，其中R1为（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷基硫基（C1-4）烷基，（C1-6）烯基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，哌啶基或吡咯烷基，R2和R4独立地为氢或可选取代的（C1-8）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，芳基，芳基（C1-4）烷基，杂环芳基或杂环芳基（C1-4）烷基，或R2和R4与它们附着的氮一起形成可选取代的哌啶基，吡咯烷基，吗啉基或哌嗪基，R3为氢或（C1-4）烷基，X1为CH2，X2为CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，其中R为氢或（C1-4）烷基，Y为（C1-8）烷基或（C1-8）烷氧基（C1-6）烷基，（C1-8）烯基或（C1-6）烯氧基（C1-6）烷基，Ar为苯环，可选取代，独立地为羟基或卤素，其中X1和X2在彼此的间位或对位，且Z为CO时，AA为天然或非天然α-氨基酸，n为0或1，或Z为SO2时，AA为可选取代的乙烯羰基（通过将氮替换为甲基烷基而来自天然或非天然α-氨基酸），n为1；制备这些化合物的方法；包含它们的制药组合物和组合物；以及它们在治疗与β-淀粉样蛋白生成和/或聚集有关的神经和血管疾病中的用途。
• MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF
  申请人：Betschart Claudia

  公开号：US20080070885A1

  公开（公告）日：2008-03-20

  The present invention relates to macro-cyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 )alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-8 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S0 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及公式（I）的大环化合物，其中R1是（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷基硫基（C1-4）烷基，（C1-6）烯基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，哌啶基或吡咯烷基，R2和R4分别是氢或可选择取代的（C1-8）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，芳基，芳基（C1-4）烷基，杂环芳基或杂环芳基（C1-4）烷基，或R2和R4与它们连接的氮一起形成可选择取代的哌啶基，吡咯烷基，吗啉基或哌嗪基，R3是氢或（C1-4）烷基，X1是CH2，X2是CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，其中R是氢或（C1-4）烷基，Y是（C1-8）烷基或（C1-8）烷氧基（C1-6）烷基，（C1-8）烯基或（C1-8）烯氧基（C1-6）烷基，Ar是苯环，可选择单取代，二取代或三取代，独立的取代基为羟基或卤素，其中X1和X2相对于彼此处于间位或对位，且Z要么是CO，AA是天然或非天然α-氨基酸，n为0或1，要么Z是S02，AA是可选择取代的乙烯基羰基基团（通过将氮替换为甲基烷基团从天然或非天然α-氨基酸衍生而来），n为1；制备这些化合物的方法；包括这些化合物的药物组合物和制剂；以及它们在治疗与β-淀粉样蛋白生成和/或聚集有关的神经和血管疾病中的用途。